Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Up 189.4% in December

Bio-Path Holdings, Inc. (NASDAQ:BPTH) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 250,000 shares, an increase of 189.4% from the December 15th total of 86,400 shares. Based on an average trading volume of 3,070,000 shares, the short-interest ratio is currently 0.1 days. Approximately 5.8% of the company’s shares are short sold.

Bio-Path Stock Up 0.8 %

Shares of Bio-Path stock opened at $0.85 on Thursday. The business’s 50 day simple moving average is $0.90 and its two-hundred day simple moving average is $1.15. Bio-Path has a one year low of $0.59 and a one year high of $10.78.

Hedge Funds Weigh In On Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC purchased a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path at the end of the most recent reporting period. 5.74% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Bio-Path in a research note on Saturday, January 11th. They issued a “sell” rating on the stock.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.